Show simple item record

dc.creatorCastillo Henríquez, Luis
dc.creatorMadrigal Redondo, German
dc.creatorVargas Zúñiga, Rolando
dc.creatorCarazo Berrocal, Gustavo
dc.date.accessioned2020-04-28T19:34:28Z
dc.date.available2020-04-28T19:34:28Z
dc.date.issued2018
dc.identifier.citationhttp://jddtonline.info/index.php/jddt/article/view/1727
dc.identifier.issn2250-1177
dc.identifier.urihttps://hdl.handle.net/10669/80935
dc.description.abstractIt is essential to guarantee physico-chemical compatibility between the active pharmaceutical ingredient (API) and the components that are planned to be used in the development of a pharmaceutical formulation. A successful compatibility study allows distinguishing between the excipients that can be used and those that may represent a risk in the quality, safety and efficacy of the medication. The present study focuses on the identification of possible incompatibilities between Rupatadine fumarate and the excipients of three formulation prototypes for the development of API´s 10 mg tablets. Samples of each raw material, placebos and preformulation mixtures were analyzed by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), X-ray diffraction (XDR) and infrared spectroscopy (IRS). The results obtained were analyzed and contrasted with the literature. Based on these, it is demonstrated that the excipients used along with the API do not generate problems in terms of compatibility, as there are no chemical changes in the drug.es_ES
dc.language.isoen_USes_ES
dc.sourceJournal of Drug Delivery and Therapeutics, vol.8(3), pp.42-54es_ES
dc.subjectActive pharmaceutical ingredientes_ES
dc.subjectChemical incompatibilityes_ES
dc.subjectCompatibility studyes_ES
dc.subjectDifferential scanning calorimetryes_ES
dc.subjectInfrared spectroscopyes_ES
dc.subjectPreformulation powder mixtureses_ES
dc.subjectRupatadine fumaratees_ES
dc.subjectThermal analysises_ES
dc.titleCombined use of DSC, TGA, XDR and NIR in the compatibility study of preformulation mixtures for the development of 10 mg tablets of Rupatadine Fumaratees_ES
dc.typeartículo científico
dc.identifier.doi10.22270/jddt.v8i3.1727
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto de Investigaciones Farmacéuticas (INIFAR)es_ES
dc.description.procedenceUCR::Vicerrectoría de Docencia::Salud::Facultad de Farmaciaes_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record